Literature DB >> 19728750

NSAID use and the risk of Parkinson's disease: systematic review and meta-analysis of observational studies.

Ali Samii1, Mahyar Etminan, Matthew O Wiens, Siavash Jafari.   

Abstract

BACKGROUND: Several studies have suggested that NSAID use may modify the risk of developing Parkinson's disease (PD).
OBJECTIVE: Our aim was to conduct a meta-analysis of observational studies evaluating NSAID use and the risk of PD.
METHODS: We systematically searched MEDLINE (1966-November 2008), EMBASE (1980-November 2008) and other databases. Data from 11 studies were included in the meta-analysis. We used the random effects model to calculate risk ratios (relative risks) and their corresponding 95% confidence intervals (CIs).
RESULTS: The pooled risk ratio of PD with NSAID use was 0.95 (95% CI 0.80, 1.12). The pooled risk ratio of PD with high-dose or long-duration NSAID use was 0.91 (95% CI 0.78, 1.05). The pooled risk ratio of PD for aspirin (acetylsalicylic acid) users was 1.08 (95% CI 0.93, 1.26). The pooled risk ratio of PD among ibuprofen users was 0.76 (95% CI 0.65, 0.89). The pooled risk ratio of PD in men using NSAIDs was 0.79 (95% CI 0.69, 0.92), and in women using NSAIDs, it was 0.72 (95% CI 0.45, 1.15).
CONCLUSIONS: NSAIDs as a class do not seem to modify the risk of PD. However, ibuprofen may have a slight protective effect in lowering the risk of PD. Although the risk ratios of PD in male and female NSAID users were similar, the 95% CI for men was suggestive of a slight risk reduction.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19728750     DOI: 10.2165/11316780-000000000-00000

Source DB:  PubMed          Journal:  Drugs Aging        ISSN: 1170-229X            Impact factor:   3.923


  28 in total

1.  Ibuprofen and the mouse model of Parkinson's disease.

Authors:  Iwona Kurkowska-Jastrzebska; Andrzej Członkowski; Anna Członkowska
Journal:  Ann Neurol       Date:  2006-06       Impact factor: 10.422

2.  Common anti-inflammatory drugs are potentially therapeutic for Parkinson's disease?

Authors:  Masato Asanuma; Ikuko Miyazaki
Journal:  Exp Neurol       Date:  2007-05-18       Impact factor: 5.330

3.  NSAID use and the risk of Parkinson's disease.

Authors:  Mahyar Etminan; Samy Suissa
Journal:  Curr Drug Saf       Date:  2006-08

Review 4.  Neuroinflammation and peripheral immune infiltration in Parkinson's disease: an autoimmune hypothesis.

Authors:  Angela J Monahan; Michael Warren; Paul M Carvey
Journal:  Cell Transplant       Date:  2008       Impact factor: 4.064

Review 5.  The role of radiotracer imaging in Parkinson disease.

Authors:  B Ravina; D Eidelberg; J E Ahlskog; R L Albin; D J Brooks; M Carbon; V Dhawan; A Feigin; S Fahn; M Guttman; K Gwinn-Hardy; H McFarland; R Innis; R G Katz; K Kieburtz; S J Kish; N Lange; J W Langston; K Marek; L Morin; C Moy; D Murphy; W H Oertel; G Oliver; Y Palesch; W Powers; J Seibyl; K D Sethi; C W Shults; P Sheehy; A J Stoessl; R Holloway
Journal:  Neurology       Date:  2005-01-25       Impact factor: 9.910

6.  Brain uptake of nonsteroidal anti-inflammatory drugs: ibuprofen, flurbiprofen, and indomethacin.

Authors:  Jagan Mohan R Parepally; Haritha Mandula; Quentin R Smith
Journal:  Pharm Res       Date:  2006-05-02       Impact factor: 4.200

7.  Combined effects of smoking, coffee, and NSAIDs on Parkinson's disease risk.

Authors:  Karen M Powers; Denise M Kay; Stewart A Factor; Cyrus P Zabetian; Donald S Higgins; Ali Samii; John G Nutt; Alida Griffith; Berta Leis; John W Roberts; Erica D Martinez; Jennifer S Montimurro; Harvey Checkoway; Haydeh Payami
Journal:  Mov Disord       Date:  2008-01       Impact factor: 10.338

8.  Nonsteroidal anti-inflammatory drugs may protect against Parkinson disease.

Authors:  Angelika D Wahner; Jeff M Bronstein; Yvette M Bordelon; Beate Ritz
Journal:  Neurology       Date:  2007-11-06       Impact factor: 9.910

9.  Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease.

Authors:  Marjolijn Bornebroek; Lonneke M L de Lau; Mendel D M Haag; Peter J Koudstaal; Albert Hofman; Bruno H C Stricker; Monique M B Breteler
Journal:  Neuroepidemiology       Date:  2007-09-11       Impact factor: 3.282

Review 10.  Glial reactions in Parkinson's disease.

Authors:  Patrick L McGeer; Edith G McGeer
Journal:  Mov Disord       Date:  2008-03-15       Impact factor: 10.338

View more
  60 in total

Review 1.  Intercellular (mis)communication in neurodegenerative disease.

Authors:  Gwenn A Garden; Albert R La Spada
Journal:  Neuron       Date:  2012-03-08       Impact factor: 17.173

2.  Risk for Parkinson's disease among patients with osteoarthritis: a Danish cohort study.

Authors:  Kathrine Rugbjerg; Søren Friis; Thomas L Jørgensen; Beate Ritz; Lise Korbo; Jørgen H Olsen
Journal:  Mov Disord       Date:  2010-10-30       Impact factor: 10.338

3.  Non-genetic factors associated with the risk of Parkinson's disease in Iranian patients.

Authors:  N Hosseini Tabatabaei; B Babakhani; A Hosseini Tabatabaei; Z Vahabi; A Soltanzadeh
Journal:  Funct Neurol       Date:  2013 Apr-May

4.  Peripheral administration of the selective inhibitor of soluble tumor necrosis factor (TNF) XPro®1595 attenuates nigral cell loss and glial activation in 6-OHDA hemiparkinsonian rats.

Authors:  Christopher J Barnum; Xi Chen; Jaegwon Chung; Jianjun Chang; Martha Williams; Nelly Grigoryan; Raymond J Tesi; Malú G Tansey
Journal:  J Parkinsons Dis       Date:  2014       Impact factor: 5.568

Review 5.  Role of α-synuclein in inducing innate and adaptive immunity in Parkinson disease.

Authors:  Heather E Allen Reish; David G Standaert
Journal:  J Parkinsons Dis       Date:  2015       Impact factor: 5.568

Review 6.  Cytochrome P450 derived epoxidized fatty acids as a therapeutic tool against neuroinflammatory diseases.

Authors:  Jogen Atone; Karen Wagner; Kenji Hashimoto; Bruce D Hammock
Journal:  Prostaglandins Other Lipid Mediat       Date:  2019-11-05       Impact factor: 3.072

7.  Vagus nerve stimulation improves locomotion and neuronal populations in a model of Parkinson's disease.

Authors:  Ariana Q Farrand; Kristi L Helke; Rebecca A Gregory; Monika Gooz; Vanessa K Hinson; Heather A Boger
Journal:  Brain Stimul       Date:  2017-08-24       Impact factor: 8.955

Review 8.  TAM receptor deficiency affects adult hippocampal neurogenesis.

Authors:  Rui Ji; Lingbin Meng; Qiutang Li; Qingxian Lu
Journal:  Metab Brain Dis       Date:  2014-12-10       Impact factor: 3.584

Review 9.  Neural and immune mechanisms in the pathogenesis of Parkinson's disease.

Authors:  Fabio Blandini
Journal:  J Neuroimmune Pharmacol       Date:  2013-02-03       Impact factor: 4.147

Review 10.  Tumor necrosis factor-alpha mediated signaling in neuronal homeostasis and dysfunction.

Authors:  Keigan M Park; William J Bowers
Journal:  Cell Signal       Date:  2010-01-21       Impact factor: 4.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.